EDX MEDICAL SIGNS EXCLUSIVE PARTNERSHIP AGREEMENT TO PROVIDE ADVANCED TESTICULAR CANCER TEST

CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today it has signed an exclusive distribution agreement with mir|detect GmbH (“mir|detect”) to distribute its M371 testicular cancer diagnostic test in the UK and Nordic markets.

The M371-Test is a simple blood test that enables highly accurate detection of critical biomarkers of testicular cancer in its early stages, the most common form of cancer among young men. More than 20,000 new cases are diagnosed each year in Europe. The test provides a highly reliable and cost-effective test solution which detects recurrences during the follow-up monitoring of patients with 100% sensitivity.  In the UK alone, there are 50,000 survivors of testicular cancer who may benefit from post-diagnosis monitoring.

The agreement between EDX Medical and mir|detect covers the UK, Sweden, Finland, Norway and Denmark.

Professor Sir Chris Evans, OBE, founder of EDX Medical Group plc, commented: "We are delighted to be partnering with mir|detect to increase patient’s access to this marvellous test which is clearly outstanding when compared with previous tests for this type of cancer. This test is an excellent addition to our rapidly growing portfolio of class-leading diagnostic solutions."

Dr Mike Hudson, CEO, EDX Medical Group plc, said: "We are very pleased to be appointed as the exclusive distributor of the M371-Test in several countries, which is an excellent fit with our range of diagnostics which enable healthcare professionals to personalise and optimise treatment decisions for all patients. EDX Medical expects to continue to work with mir|detect in future to further refine and develop the test and associated services.”

Dr Nina Winter, CEO, mir|detect commented: "The M371-Test provides faster and more reliable diagnosis of testicular germ cell tumours. It is minimally invasive, patient friendly and has a very high and reliable detection of recurrence in patients. We are delighted to have established our new relationship with EDX Medical.”